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Background: This study evaluates the concept of optimizing ventricular pacing in regard to functional
cardiac response. Lead implant based on physiologic variables of contractility at various sites was
performed in patients with and without congenital heart disease (CHD). Since right ventricular apical
pacing may adversely alter contractility and myocellular function, septal and outflow tract pacing have
been advocated. However, there are few studies in the young and essentially none in those with CHD.
Methods:A total of 113 consecutive patients with andwithout repaired CHD, aged two to 51 (median 16),
some with preexisting epicardial pacemakers, underwent transvenous pacemaker implant using standard
sensing/pacing indices plus measurements of pressures, QRS, and contractility responses at each of five
predefined potential ventricular implant sites: apex, inflow-, low-, mid-, and infundibular/outflow-septal
with each patient serving as his/her own control. Implant was at the site of best contractility with active-
fixation, low-threshold steroid-eluting leads.
Results: Measured contractility indices varied up to 31% (mean 12%) between sites per patient. Septal
regions (mid-, inflow-, and low-) were associated with the most optimal and right ventricular epicardial
showed the worst contractility (P < 0.05) responses. Apex was optimal in some CHD patients. Threshold
and sensing were comparable up to 11 years (mean 7) postimplant regardless of septal site.
Conclusion: There is no single “sweet spot” for optimal ventricular pacing, and the best implant sites are
patient and CHD variable. Current lead designs ensure chronic stability/performance regardless of site.
Proactive contractility-guided pacing implant can optimize chronic paced ventricular function. (PACE
2015; 38:54–62)
pediatrics, pacing, hemodynamics
Introduction
The original applications of transvenous ven-
tricular pacing were performed with endocardial
leads having limited electrode fixation capabilities
which resulted in frequent dislodgements. In
this regard, the right ventricular apex offered
technical simplicity of implant with stability of
electrode performance, with ready-application to
pacing children and young adults.1–4 However,
initiation of paced electrical impulse propagation
from this apical region is associated more with
muscle than His-Purkinje conduction, causing
asynchronous right and left ventricular (LV) con-
traction. Ventricular function may be modified by
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pacing rate, atrioventricular activation coupling
intervals, and pacing site. Therefore, each of
these variables has found interest in both animal
and clinical studies to improve paced myocardial
performance. Right ventricular (RV) apical pacing,
with its resultant paced left bundle branch QRS
configuration, causes multiple recognized adverse
effects that include paradoxical septal motion,
elevated LV pressures, decreased contractility,
altered coronary flow, decreased cardiac output,
and structural myocellular remodeling.5–8 Over
time, this remodeling may adversely contribute
to histopathologic changes that eventually affect
function.9–12 As advocated as early as 1925, pacing
electrode placement in close proximity to the
normal conduction system offers the potential
for improved ventricular function by optimizing
biventricular (BiV) contractility.13 More recently,
studies have demonstrated that pacing site, and
therefore the initiation of ventricular contractility,
may be the prime contributor to function.14–16 Con-
tractility measurements have included pressure-
volume loops as well as the first derivative of
©2014 Wiley Periodicals, Inc.
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systolic pressure17–20 which additionally has had
pertinent impact with interest in resynchroniza-
tion pacing for heart failure.
With the introduction of improved low
threshold and steerable pacing lead designs
permitting fixation at nearly any ventricular
location, there has been an increased interest
in alternate or select site pacing. Various right
ventricular sites ranging from the inflow to
outflow/infundibular septum, bundle of His, and
midseptal moderator band have been studied.21–26
Unfortunately, precise identification of each site
has not been uniform in the literature, leading to
some confusion as to the exact location advocated
per study. As a result, “septal” pacing, as a distinct
anatomical location, has limited application. The
purpose of this study was to evaluate comparative
indices of paced systemic ventricular contractility,
using the first derivative of systolic pressure
(dP/dt), as well as more standard evaluations
of pressures and QRS morphology, among five
distinct ventricular lead insertion “septal” as
well as apical sites in younger patients with
and without repaired congenital heart disease
(CHD) undergoing pacemaker implant in order to
ascertain the most optimal implant site yielding
the best physiologic paced response. Chronic lead
performances at these sites were then compared
over time.
Methods
This was a retrospective study conducted at
The Children’s Hospital of Michigan, Section of
Cardiology. The study was approved by the In-
stitutional Review Board, Wayne State University
School of Medicine/Detroit Medical Center. The
inclusion criteriawere all patientswho underwent
a transvenous pacing system for symptomatic
bradycardia associated with atrioventricular block
(AVB). Patients included those with repaired
CHD as well as preexisiting right ventricular
free wall epicardial pacing systems that were
changed to a transvenous system for various
indications, including epicardial lead fracture. All
patients were studied using the same institutional
pacemaker implant protocol, which, especially
since many patients had repaired congenital
heart, included a hemodynamic catheterization
study with venograms to assess vascular access
patency.
After informed consent was obtained, all pa-
tients received appropriate sedation, heparinized
intravenous fluids (2000 units/500 cc), and antibi-
otic coverage as recommended. Per institutional
protocol for device implantation, all patients were
intubatedwith controlled ventilation. This limited
any respiratory effects onmeasured hemodynamic
variables. The femoral vein and artery were en-
tered using standard percutaneous techniques and
catheters inserted to permit continuous systemic
arterial and ventricular pressure monitoring as
well as to provide temporary pacing as required.
Both right and left cardiac hemodynamics were
recorded. A flexible quadripolar pacing catheter,
EPT SterroCath model 2001 (Boston Scientific,
Natick, MA, USA), was placed in the systemic
venous ventricle for temporary pacing. The
systemic ventricular pressure recording catheter
was connected to either a Cathcor Model 2.2,
or Sensis system (Siemens, Munich, Germany)
with online program capability of measuring
instantaneous waveforms of ventricular pressure
as well as waveform analysis of indices of ventric-
ular contractility (dP/dt and dP/dt/p). Continuous
surface electrocardiogram (ECG) tracings were
recorded.
The initial superior vena cava/innominate
venogram performed to delineate vascular patency
was stored for viewing. In the anterior-posterior
(AP) image, a perpendicular line was then created
to intersect the midtricuspid valve with the
ventricular septal surface (Fig. 1). This intersect
region was defined as the midseptal area approx-
imating the moderator band location in patients
with normal right ventricular morphology and
comparable ventricular regions in those with con-
genital corrected transposition of the great arteries
(L-TGA) with LV morphology of the systemic
venous ventricle. In patients who had undergone
the Mustard procedure for D-transposition of the
great arteries (D-TGA), the venogram permitted
delineation of the LV septal surface to serve as a
comparable marker for lead implant. The apical
to semilunar valve distance along the septum
was then subdivided into the five mentioned
regions (Fig. 1). Once the venous hemodynamics
and venogram studies were performed, a stan-
dard pigtail 4-Fr or 5-Fr hemodynamic catheter
(Cook Medical, Bloomington, IN, USA) was then
advanced into the systemic arterial ventricle for
pressure and contractility measurements. Due to
the anticipated short time to evaluate systemic
function, combined with a heparinized saline
flush solution, activated clotting time (ACT) levels
were not routinely obtained.
In a randomized fashion, the flexible pacing
catheter was then advanced to each of the
five separate potential septal implant sites as
previously described: apex, low septum between
the defined midseptum and apex, midseptal,
infundibular/outflow septum between the mid-
septum and semi-lunar valve, and inflow septum
approximating the region of the bundle of
His/proximal septum. Use of biplane fluoroscopy
permitted accurate positioning along the septum
with avoidance of the more anterior ventricular
PACE, Vol. 38 January 2015 55
KARPAWICH, ET AL.
Figure 1. Schematic representation of right ventricular septal lead implant sites as visualized
following angiographic appearance in the AP projection (left). Temporary pacing catheters are
visualized. Lines are drawn from the midtricuspid valve to intercept the septal surface from apex
to outflow to demarcate regions as indicated. AP = apex; IS/H = inflow septum/His; LS = low
septum; MS = midseptum; OS = outflow septum; PV = pulmonary valve; TV = tricuspid valve.
free wall. Each patient served as his/her own con-
trol. For baseline and for each pacing site, the fol-
lowing protocol was initiated: physiologic indices
of ventricular systolic and diastolic pressures,
dP/dt, dP/dt/p, and surface ECGQRS duration and
axis were recorded. Among patients with AVB and
an adequate intrinsic rate, these baselines values
were recorded during the patient’s own rhythm.
Among those patients with surgical complete AV
block and a preexisting epicardial pacing system,
baseline values were recorded by programming
the pulse generator to slower heart rates only if
the intrinsic rate was adequate to prevent any
hemodynamic compromise. Otherwise, an age-
appropriate paced rate was chosen.
Following 3–5 minutes of pacing with
observation to ensure hemodynamic stability,
pressures and contractility indices were recorded
and the temporary pacing catheter was then
randomly positioned at one of the other potential
implant sites and comparative physiologic indices
recorded during repeat pacing protocols at the
same rates. To ensure reliability of the recorded
data, at least three separate measurements of
contractility variables were obtained per pac-
ing site, and the average recorded. Following
permanent lead implant, a repeat contractility
measurement was performed. This procedure
was repeated at age-appropriate paced rates per
patient until data had been obtained from all
potential implant sites. Intracardiac electrograms
of Purkinje potentials were not specifically sought
or evaluated during the mapping protocols. Due
to persistent controversy over electrical versus
mechanical correlates of contractility,25 dP/dt was
chosen as the single best indicator in those cases
when a discrepancy arose between QRS duration
and dP/dt. This was especially true among
patients with preexistent surgical bundle branch
block.
Following evaluation of best site, a fluoro-
scopic image was saved, the systemic ventricular
catheter was removed, and utilizing standard ster-
ile surgical techniques, a standard subclavicular
pocket and pacemaker implant was performed.
As determined by vessel size, either the cephalic,
subclavian, or axillary vein was entered and the
chosen pacing lead inserted and advanced to the
appropriate venous ventricle using biplane flu-
oroscopic guidance. Various steroid-eluting, low
threshold, silicone- and polyurethane-insulated,
active fixation leads, including the newer M3830
catheter-delivered lead (Medtronic Inc., Min-
neapolis,MN,USA)were implanted depending on
patient size. In each patient, the lead was secured
to the preselected area followed by standard
sensing and threshold measurements, pulse gen-
erator insertion, and pocket closure. Postimplant
follow-up ranged from 5 years to 11 years
(mean 7).
Statistics compared recorded results at each
temporary implant site in each patient and
between all patients as a group using the
Student paired and nonpaired t-test (GraphPad
Software, Inc., La Jolla, CA, USA). Significance
was described at a P value < 0.05.
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Figure 2. Exemplary fluoroscopic appearances of lead implant sites along the mapped right
ventricular septal areas as viewed in the frontal plane. (A) Apex. (B) Low septum. (C) Midseptum.
(D) Infundibular/outflow septum.
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Figure 3. Pie diagram illustrating percent breakdown of
themost optimal ventricular implant sites overall, based
on measured contractility index (dP/dt) regardless of
anatomy.
Results
A total of 113 consecutive patients, aged
2–51 (mean 17 years) were studied. Of these, 46
had various repaired congenital heart defects that
included ventricular septal defects (16 patients)
or tetralogy of Fallot (TOF; 10 patients) and D-
transposition of the great arteries with theMustard
intraatrial baffle (nine patients) or Jatene arterial
switch (five patients) procedures. Other repaired
CHD included valve surgeries (six patients).
The nonsurgical patients included congenital
AVB (CAVB), of whom three patients had
congenitally corrected transposition or L-TGA. A
preexisting right ventricular free wall epicardial
pacing system was present in 26 patients. There
were no adverse events following the temporary
pacing protocol, which added approximately
20 minutes to the implant time. Permanent
pacemaker implant was not associated with
any complications. There was neither excessive
bleeding nor pocket hematomas. Depending on
design, all preselected implant siteswere achieved
without complications using appropriately curved
stylets or, in instances of the M3830 lead (60%
of leads used), the Select SiteTM catheter delivery
system.
With each patient serving as his/her own
control, the most optimal lead implant site
producing the best ventricular contractility was
found to be variable from right ventricular apex to
infundibular/outflow septum among all patients
and congenital heart defects. This was espe-
cially true in patients with repaired congenital
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Table I.
Best Pacing Implant Site Comparisons (Mean Values ± SEM)
RV Low Inflow Outflow Left RV
Total Apex Septum Midseptum Septum Septum Ventricle† Epicardial‡
No. of patients 113 11 20 41 22 10 9 26
dP/dt§ 988 907 993 1,065 960 925 846 800*
± 24 ± 73.8 ± 69 ± 38 ± 49 ± 102 ± 50 ± 75
dP/dt/p 27 26 27 25 27 27 25 24*
± 0.6 ± 2.1 ± 1.8 ± 1.0 ± 1.2 ± 2.2 ± 2.1 ± 1.9
Th (V)¶ 0.6 0.6 0.6 0.7 0.6 0.9* 0.5 0.7
± 0.3 ± .06 ± .09 ± .05 ± .05 ± 0.1 ± .08 ± 0.06
R wave (mv) 11.9 10.9 10.7 13.2 10.5 14.9 9.8 10.7
± 0.6 ± 1.0 ± 1.4 ± 1.1 ± 1.2 ± 2.4 ± 1.7 ± 1.2
QRS (ms) 124 122 128 124 113* 138 128 146*
± 2.2 ± 12.6 ± 4.8 ± 3.0 ± 3.8 ± 7.9 ± 8.4 ± 6.9
EDP (mm Hg) 10 11 9 9 10 14 9 11
± 0.3 ± 1.4 ± 0.8 ± 0.5 ± 0.7 ± 1.7 ± 0.8 ± 0.9
*P < 0.05 compared with all other groups.
†Paced venous ventricle with “left” morphology (D/L TGA), dP/dt of systemic “right” ventricle.
‡Prexisting RV epicardial systems.
§mm Hg-s; systemic ventricle function.
¶At 0.5 ms.
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Figure 4. Pie diagrams showing percentage of best right ventricular implant sites based on contractility by implant
location among patients specifically with repaired septal defects/surgical AV block and nonsurgical (e.g., congenital
AVB) congenital heart. (Left) Patients with septal defect repair, including tetralogy of Fallot. (Right) Patient without
previous surgery.
heart disease. As seen in Table I, indices of
contractility (dP/dt, dP/dt/P) did differ between
sites among patients with or without CHD.
Measured differences in contractility associated
with pacing sites ranged from 5% up to 31%
(mean 12%) between the best and worst implant
site location per patient. When compared by site
(apex, low septum, etc.), no intracardiac site was
shown to be more or less optimal than another
with mean contractility differences of 11–13%
per site, indicating that patient factors and not
site, per se, are the most important variables.
Analysis of the most optimal pacing site based
on anatomy are shown in Figures 1–4. Among all
patients, the midseptal locations, approximating
either the defined midseptal moderator band,
inflow or low septal regions, were associated
with the best hemodynamic responses compared
with either the ventricular apical and distal
infundibulum/outflow sites. Among patients with
repaired ventricular septal defects, the inflow
septal region was shown to be less optimal with
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only 8% of patients exhibiting the best contrac-
tility measurements from that paced location.
This group also showed that in 15% of patients,
the apical site offered improved contractility.
Since there were only nine patients with D-
TGA/Mustard repair, any valid comparison of LV
sites was not possible. Following permanent lead
insertion, repeat contractility measurements were
comparable to the prelead implant value.
End-diastolic pressures were not significantly
different among mapped sites or when compared
with intrinsic values. Although there were some
variations in paced QRS duration, the only
significant differences were seen among those
patients with inflow septal pacing in which the
QRS shortened and those with preexisting right
ventricular epicardial pacing in which the QRS
was prolonged (P< 0.05). Epicardial right ventric-
ular pacing was also associated with significantly
worse contractility compared with all other sites
(P < 0.05). Sites between the midseptal and apical
regions were typically associated with a leftward
or superior QRS axis, whereas regions between
the midmoderator and semi-lunar valve exhibited
a more normalized QRS axis. Sensed implant R
waves did not differ significantly between sites.
Implant thresholds also were comparable between
sites except for the outflow region that was higher
but still acceptable at less than 1 Volt.
Follow-up evaluations from 5 years to 11
years (mean 7) did not demonstrate any lead
dislodgements or appreciable changes in pacing
threshold, R-wave sensing, or lead impedances
regardless of pacing site or lead used. No repro-
gramming to compensate for any adverse lead
performance problems was required. There was
no evidence of clinical contractility deterioration
among patients. Follow-up echocardiographic
measurements, as a whole, did not illustrate
any appreciable differences from initial values.
During this time interval, follow-up hemodynamic
catheterization studies were performed in six
patients, 16–22 years of age (mean 18), at the
time of generator replacement for battery depletion
or other clinical issues. Repeat measurements
with temporary pacing showed that the initially
chosen implant site still demonstrated the best
contractility with site comparisons of dP/dt
ranging from 5% to 33% (mean 22%).
Discussion
As an index of ventricular function, dP/dt
reflects peak contractility, elasticity, and
ventricular dimensions. Since it is attained
before aortic valve opening, the measured value
is independent of afterload. However, there may
be some preload dependence. For this reason, the
value of dP/dt/p, which incorporates developed
isovolumic pressure and negates any preload
interference, was also studied with the patient in
a sedated physiologic steady state with controlled
respirations. In this regard, initiation of ventric-
ular contraction via pacing site was the more
important variable that any atrial contribution
to ventricular filling, per se. Contractility was
measured during single site ventricular pacing.
Current physiologic recording catheterization
laboratory equipment permits relatively simple
and reproducible on-line acute evaluations of
preimplant LV contractility performance indices,
which may translate into chronic clinical benefits.
Although the mapping protocol may lengthen
the implant procedure time when compared with
a typical ventricular apical lead implant not
accompanied by hemodynamic measurements,
optimization of lead implant offers the potential
for improved chronic ventricular performance.
Initial pacemaker application concerns of lead
stability, integrity, pacing threshold, and generator
battery/circuitry have been largely satisfied over
the past three decades of technologic advances.26
Ventricular electrical activation and consequent
LV function have only recently enjoyed a resur-
gence of interest, due primarily to the increasing
body of evidence that chronic right ventricular
apical pacing can be associated with adverse
physiology and altered cardiac histopathology that
may contribute to patient morbidity andmortality.
These concepts have led to interest in septal,
alternate, or select-site as well as multisite pacing
to either improve the failing myocardium or
prevent future pacing-related dysfunction.27 The
multiple recent trials of cardiac resynchronization
therapy (CRT) or BiV pacing substantiate improve-
ment in ischemic and nonischemic (or idiopathic)
myocardial dysfunction in some selected patients
with advanced heart failure.28,29 These concepts
have recently been applied in a very limited
capacity to younger patients, with and without
congenital heart defects, as a potentially effective
therapy to improve hemodynamics or as an
alternative to heart transplant.30–32 However,
CRT/BiV pacing is a retroactive approach for an
already depressed contractile condition and may
not be as necessary in younger patients as in
older patients with myocardial dysfunction, if
more precise ventricular pacing sites that optimize
ventricular performance can be established from
the time of initial pacemaker application.
In CRT trials, a 5–10% increase in LV ejection
fraction (EF) has been indicated as a marker for a
positive response to therapy. However EF, espe-
cially among patients with regional asynchrony,
such as with preexisting paced rhythm, bundle
branch block, or postsurgical septal patches,
becomes less accurate and valid as an effective
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measurement of contractility.33 As a result, this
study did not utilize any indirectly calculated
echocardiographic parameters of measured func-
tion, but relied on more direct hemodyanmic
measurements. In this regard, contractility indices
varied from 5% to 31% between implant sites.
Such changes are in accord with published CRT
reports indicating benefit, and, as such, the site
associated with the best contractility response
should be sought to optimize paced myocardial
function.
Prevention of myocardial dysfunction by a
more proactive approach to initial pacemaker
application is a less-established clinical applica-
tion than standard implant protocols. However,
such an approach is perhaps more applicable to
younger patients in whom pacing may be antici-
pated to be required for a more protracted period
than in elderly patients. In this regard, initial lead
implant optimization with direct measurements
of physiologic responses appears to be a prudent
approach, as there was up to a 31% difference
in measured contractility indices between the
best and worst implant site. Although, ideally,
all patients would have undergone a follow-up
hemodynamic study after implant to confirm site
efficacy, due to clinical issues, only a few were
able to be studied. Nevertheless, the initially
chosen site still exhibited the most optimal
contractility response among those patients. This
study also confirms previous reports of adverse
contractility associated with RV epicardial free
wall pacing.34
Not unexpectedly, CHD patients with surgi-
cally repaired septal defects (including TOF) en-
compassed the largest group requiring permanent
pacing. Unfortunately, other represented CHD
anatomies were too few to make any definitive
comparisons of optimal pacing site. That will be
work for future studies. Of interest, and perhaps
not unexpected, the RV apex was shown to be the
more optimal implant site in a few patients with
repaired CHD, especially considering septal patch
materials used for septal defect closure. Following
septal defect repair, extensive fibrotic changes
along the septum may preclude any effective lead
implant as well as contribute to regional wall
motion abnormalities. Of these 11 patients with
optimal apical pacing sites, nine had previous
septal defects repaired resulting in regional septal
wall dyssynchrony. This finding does emphasize
the need to ascertain site optimization prior to
simply assuming, for example, that RV apical
pacing is potentially detrimental in all patients.
In addition, although the numbers are small,
patients in whom the systemic ventricle was of
a “right” ventricle morphology, such as among
those following the Mustard repair for D-TGA,
showed decreased contractility when compared to
other CHD with a systemic “left” ventricle. Larger
numbers of patients will be required to determine
any significance among this group and others
with repaired CHD. Nevertheless, since early heart
failure can be expected in some adult patients
with various repaired congenital heart defects,
optimization of paced myocardial function should
be sought to potentially improve chronic clinical
well-being.
Although many studies have advocated right
ventricular outflow tract pacing, precise definition
of this anatomic region is often not specified.
For this reason, any location from the low
septal to subpulmonic infundibular regions can
be interpreted as the outflow tract. This study
subdivides the septal surface into regions. Results
confirm that this is a diverse area and pacing
from each site results in different ventricular
performance indices as previously reported from
pressure-volume loop studies.19 Since ventricular
anatomy is not a constant variable, especially
in CHD, and normal variations in structure are
commonly found, for example, absence of an
identifiable moderator band, it is mandatory for
a more precise definition of the implant site.
This especially applies to patients with diverse
cardiac anatomy. It was reassuring that the current
generation of low threshold, steroid-eluting pacing
leads exhibited stable performances regardless of
implant site.
Precision of implant location, based on
several variables, can provide a better approach
to implant. QRS duration may have some associa-
tion with myocardial performance as previously
reported. However, duration alone may not be
the best indicator of mechanical contractility.34
This was confirmed in this study. Except for
the inflow site, QRS duration was not found
to be of any appreciable value in correlation
with contractility. As a result, other invasive
and noninvasive parameters of contractility such
as conductance, pressure-volume loops, tissue
Doppler, and velocity-time integral have been
utilized with variable success. However, use of
these measured indices can significantly increase
implant time as well as the requirement for equip-
ment not necessarily found in standard cardiac
catheterization laboratories. This study utilized
readily available on-line dP/dt and dP/dt/p
measurement values, which are relatively pre- and
afterload insensitive, permitting technical ease
by use of standard intravascular catheters with
objective findings. Unfortunately, to date, there
has been no concise agreement on the single best
implant variable that has been shown to predict
chronic effects of physiologic performance. More
prospective studies will be required in this regard.
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Study Limitations
This is the first study that presents a proactive
approach to selective transvenous ventricular lead
implantation in the young, with and without
repaired CHD, based on contractility response.
Although this technique requires a hemodynamic
catheterization study, which is recommended for
any patient with repaired congenital heart, the use
of standard cardiac catheterization hemodynamic
measuring equipment permits ease of obtaining
contractility indices values. However, originating
from a single congenital heart center, patient
numbers are limited when compared with other
published multicenter studies. In addition, due
to patient care issues, follow-up contractility
measurements could only be performed when
indicated for other reasons, such as generator
replacement. As a result, there are limited chronic
comparisons. An expanded study in patients
from multiple congenital heart centers will be
required before any definitive standards for lead
implant in the patientswith andwithout structural
congenital heart defects can be determined. And
since adverse effects of pacing may require many
years before any adverse changes are expressed
by known objective noninvasive clinical testing,
an extended follow-up interval will be required
to determine if select site pacing based on initial
implant variables will prevent or lessen reported
adverse changes. The population of adults with
CHD is only increasing. Optimization in all aspects
of therapeutic care delivery is mandatory.
Conclusions
Although not universally applicable to all
patients, a midseptal ventricular implant site may
offer the best paced ventricular contractility. How-
ever, “best-site” is patient and CHD variable. More
precise lead implant locations with measurement
of physiologic response should be explored to
both optimize systemic ventricular performance
and potentially prevent eventual adverse changes.
Such studies add little extra time to an implant.
Optimizing lead implantation based on systemic
ventricular physiologic responses, at least acutely,
may be a promising approach to lead implant
protocols. Chronic follow-up will be required
to determine if the reported adverse changes
associatedwith pacing also occur following pacing
at these alternative selected sites in a growing
patient population with and without congenital
heart defects.
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